IP Library Granted Patent US 10,314,837
Granted Patent B2
US 10,314,837 · App. 15/197,336 · Granted Jun 11, 2019

Subcutaneous delivery of poly(oxazoline) polymer conjugates

Inventors: Randall Moreadith (Huntsville, AL); Michael David Bentley (Huntsville, AL); Kunsang Yoon (Huntsville, AL); Zhihao Fang (Madison, AL); Rebecca Weimer (Huntsville, AL); Bekir Dizman (Huntsville, AL); Tacey Viegas (Madison, AL)
Assignee: Serina Therapeutics, Inc.
A61K31/4745A61K9/0019A61K31/381A61K31/4045A61K31/4462A61K31/4535A61K31/7048A61K47/542A61K47/60A61K47/61
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,314,837
App. No.
15/197,336
Granted
Jun 11, 2019
Kind
B2
Abstract

The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a hydrolyzable moiety.

Claims (35)

1. A poly(oxazoline) polymer conjugate, the poly(oxazoline) polymer conjugate having the structure

wherein

L is

R 3 forms a linkage with the poly(oxazoline) polymer chain;

R 4 is —CH 2 —C(O)—O—, —CH(CH 3 )—C(O)—O—, —CH 2 —CH 2 —C(O)—O—, —CH 2 —CH 2 —CH 2 —C(O)—O—, —CH 2 —O—C(O)—, —CH(CH 3 )—O—C(O), —CH 2 —CH 2 —O—C(O)— or —CH 2 —CH 2 —CH 2 —O—C(O)—;

R is an initiating group;

R 1 is a non-reactive group;

A is rotigotine;

a is ran which indicates a random copolymer or block which indicates a block copolymer;

o is from 1-50;

m is from 1-1000;

T is a terminating group; and

the conjugate provides a release profile for rotigotine that is dependent on the selection of R 4 .

2. The polymer conjugate of claim 1 , wherein the poly(oxazoline) polymer has a molecular weight range of 300 Da to 200,000 Da.

3. The polymer conjugate of claim 1 , wherein R 3 is —C(O)—(CH 2 ) 3 and R 4 is —CH 2 —C(O)—O—, —CH 2 —CH 2 —C(O)—O—, —CH(CH 3 )—C(O)—O— or —CH 2 —CH 2 —CH 2 —C(O)—O—.

4. The polymer conjugate of claim 1 , wherein L has the structure

5. The polymer conjugate of claim 1 , wherein T is —Z—B-Q

wherein

Z is S, O, or N;

B is an optional linking group; and

Q is a terminal portion of a terminating nucleophile.

6. The polymer conjugate of claim 1 , wherein R is hydrogen, alkyl or substituted alkyl.

7. The polymer conjugate of claim 1 , wherein R 1 is an alkyl or substituted alkyl.

8. The polymer conjugate of claim 1 , wherein the rotigotine is (−)rotigotine.

9. The polymer conjugate of claim 1 , wherein the release profile provides a controllable delivery of the rotigotine over a period of days to weeks.

10. The polymer conjugate of claim 1 , wherein the release profile provides a controllable delivery of the rotigotine over a period of weeks.

11. The polymer conjugate of claim 1 , wherein R 3 is —C(O)—(CH 2 ) 3 — and R 4 is —CH 2 —CH 2 —C(O)—O—.

12. The polymer conjugate of claim 1 , wherein R 3 is —C(O)—(CH 2 ) 3 — and R 4 is —CH(CH 3 )—C(O)—O—.

13. The polymer conjugate of claim 1 , wherein R 3 is —C(O)—(CH 2 ) 3 — and R 4 is —CH 2 —C(O)—O—.

14. The polymer conjugate of claim 1 , wherein R 1 is —CH 3 or —CH 2 CH 3 .

15. The polymer conjugate of claim 1 , wherein T is —SCH 2 CH 2 —COOH.

16. The polymer conjugate of claim 1 , wherein R 1 is alkyl or substituted alkyl, T is —SCH 2 CH 2 —COOH and R is H, alkyl, or substituted alkyl.

17. The polymer conjugate of claim 4 , wherein R 1 is alkyl or substituted alkyl, T is —SCH 2 CH 2 —COOH and R is H, alkyl, or substituted alkyl.

18. The polymer conjugate of claim 1 , wherein R 1 is —CH 3 or —CH 2 CH 3 , T is —SCH 2 CH 2 —COOH and R is H or —CH 3 .

19. The polymer conjugate of claim 4 , wherein R 1 is —CH 3 or —CH 2 CH 3 , T is —SCH 2 CH 2 —COOH and R is H or —CH 3 .

Assignments (2)
CHANGE OF NAME Recorded Apr 12, 2024
From: SERINA THERAPEUTICS, INC.
To: SERINA THERAPEUTICS (AL), INC.
Reel/Frame 067084/0859 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2019
From: MOREADITH, RANDALL; BENTLEY, MICHAEL DAVID; YOON, KUNSANG; FANG, ZHIHAO; WEIMER, REBECCA; DIZMAN, BEKIR; VIEGAS, TACEY
To: SERINA THERAPEUTICS, INC
Reel/Frame 048168/0217 →
Continuity (5)
Continuation 14094425 · Dec 2, 2013
Continuation 13774304 · Feb 22, 2013
Continuation 13524994 · Jun 15, 2012
Provisional Application 61554336 · Nov 1, 2011
Related Publication 20160303250A1 · Oct 20, 2016
Cited By (1)
US 12,714,704